Shopping Cart
Remove All
Your shopping cart is currently empty
Tremelimumab
😃Good
Catalog No. T77466Cas No. 745013-59-6
Alias Ticilimumab, CP-675206
Tremelimumab is a cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) blocking antibody.Tremelimumab is often used in combination with Durvalumab for the treatment of solid cancers such as hepatocellular carcinoma and lung cancer.
Tremelimumab
😃Good
Catalog No. T77466Alias Ticilimumab, CP-675206Cas No. 745013-59-6
Tremelimumab is a cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) blocking antibody.Tremelimumab is often used in combination with Durvalumab for the treatment of solid cancers such as hepatocellular carcinoma and lung cancer.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $155 | In Stock | In Stock | |
| 5 mg | $472 | In Stock | In Stock | |
| 10 mg | $690 | - | In Stock | |
| 25 mg | $1,080 | - | In Stock | |
| 50 mg | $1,460 | Inquiry | Inquiry | |
| 100 mg | $1,970 | Inquiry | Inquiry |
Add to Cart
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Batch Information
Select Batch
Purity:95.3% (SDS-PAGE); 98.7% (SEC-HPLC)
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
Antibody Information
Storage & Solubility Information
| Description | Tremelimumab is a cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) blocking antibody.Tremelimumab is often used in combination with Durvalumab for the treatment of solid cancers such as hepatocellular carcinoma and lung cancer. |
| In vitro | Tremelimumab exhibits a higher binding affinity for CTLA-4-Ig compared to CD28-Ig, demonstrating specificity for cynomolgus monkeys and humans. It does not engage with human leukocyte FcγR, mitigating the risk of cytokine release syndrome. Interestingly, Tremelimumab enhances IL-2 production in a concentration-dependent manner when stimulated with staphylococcal enterotoxin A, showcasing its ability to modulate T-cell responses.[1] |
| Synonyms | Ticilimumab, CP-675206 |
| Reactivity | Human |
| Application | Functional assay |
| Antibody Type | Monoclonal |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Gene ID | |
| Uniprot ID | |
| Target | CTLA-4/CD152 |
| Molecular Weight | 146.3 kDa |
| Cas No. | 745013-59-6 |
| Isotype | Human IgG2 kappa |
| Recommended Isotype Control |
| Storage | store at low temperature | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Calculator
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: buy Tremelimumab | purchase Tremelimumab | Tremelimumab cost | order Tremelimumab | Tremelimumab chemical structure | Tremelimumab in vitro | Tremelimumab molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.